Unknown

Dataset Information

0

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.


ABSTRACT: Survival for patients with acute myeloid leukemia (AML) is limited by treatment-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation (HCT). Natural killer (NK)-cell alloreactivity, determined by donor killer-cell immunoglobulin-like receptors (KIRs) and recipient HLA, correlates with successful HCT for AML. Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: at least 1 B haplotype) would affect outcomes, we genotyped donors and recipients from 209 HLA-matched and 239 mismatched T-replete URD transplantations for AML. Three-year overall survival was significantly higher after transplantation from a KIR B/x donor (31% [95% CI: 26-36] vs 20% [95% CI: 13-27]; P = .007). Multivariate analysis demonstrated a 30% improvement in the relative risk of relapse-free survival with B/x donors compared with A/A donors (RR: 0.70 [95% CI: 0.55-0.88]; P = .002). B/x donors were associated with a higher incidence of chronic graft-versus-host disease (GVHD; RR: 1.51 [95% CI: 1.01-2.18]; P = .03), but not of acute GVHD, relapse, or TRM. This analysis demonstrates that unrelated donors with KIR B haplotypes confer significant survival benefit to patients undergoing T-replete HCT for AML. KIR genotyping of prospective donors, in addition to HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes.

SUBMITTER: Cooley S 

PROVIDER: S-EPMC2628378 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Cooley Sarah S   Trachtenberg Elizabeth E   Bergemann Tracy L TL   Saeteurn Koy K   Klein John J   Le Chap T CT   Marsh Steven G E SG   Guethlein Lisbeth A LA   Parham Peter P   Miller Jeffrey S JS   Weisdorf Daniel J DJ  

Blood 20081022 3


Survival for patients with acute myeloid leukemia (AML) is limited by treatment-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation (HCT). Natural killer (NK)-cell alloreactivity, determined by donor killer-cell immunoglobulin-like receptors (KIRs) and recipient HLA, correlates with successful HCT for AML. Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: at least 1 B haplotype) would affect outcomes, we genotyped donors and recip  ...[more]

Similar Datasets

| S-EPMC5501362 | biostudies-literature
| S-EPMC8802570 | biostudies-literature
| S-EPMC7042994 | biostudies-literature
| S-EPMC1894998 | biostudies-literature
| S-EPMC2662650 | biostudies-literature
| S-EPMC4768474 | biostudies-literature
| S-EPMC4031316 | biostudies-literature
| S-EPMC3972059 | biostudies-literature
| S-EPMC2917308 | biostudies-other
| S-EPMC4920429 | biostudies-literature